MétaCan
Menu
Back to cohort
Record W4414717317 · doi:10.3389/fendo.2025.1680281

Adverse events of the thyroid peroxidase inhibitor methimazole in the treatment of hyperthyroidism: a comprehensive analysis from the first quarter of 2004 to the first quarter of 2025

2025· article· en· W4414717317 on OpenAlexaboutno aff
Yixin Sun, Shuai Wang, Xu Zhou

Bibliographic record

VenueFrontiers in Endocrinology · 2025
Typearticle
Languageen
FieldMedicine
TopicThyroid Disorders and Treatments
Canadian institutionsnot available
FundersNatural Science Foundation of Fujian Province
KeywordsAdverse effectMethimazoleQuarter (Canadian coin)Graves' diseaseThyroidAntithyroid agent

Abstract

fetched live from OpenAlex

Purpose: The primary objective of this study is to systematically monitor and comprehensively characterize adverse events (AEs) associated with methimazole, which is utilized in the treatment of hyperthyroidism. Method: A comprehensive analysis of the US FDA Adverse Event Reporting System (FAERS) database was conducted, covering data from the first quarter of 2004 to the first quarter of 2025. Multiple signal detection algorithms, including the ROR, PRR, BCPNN, and EBGM, were employed for conduct disproportionality analysis to efficiently mine the data and accurately identify signals associated with AEs related to methimazole. Result: After analyzing 1,908 patient cases with 6,449 reported AEs linked to methimazole, the study confirmed AEs like agranulocytosis, pyrexia, hypothyroidism, and drug-induced liver injury aligning with the drug's package insert. Interestingly, several previously unreported AEs, such as premature baby, polyarthritis, pleural effusion, septic shock, cholestasis and jaundice cholestatic were identified. The findings indicate potential unrecognized AEs and highlight the importance of continued pharmacovigilance and rigorous drug safety surveillance. The median onset time of methimazole related AEs was 27 days (interquartile range [IQR]: 5-58 days), indicating that the majority of cases occurred early after initiating use methimazole. Conclusion: This study confirms that agranulocytosis, pyrexia, exposure during pregnancy, and hyperthyroidism are AEs associated with methimazole use. It also identifies new safety signals, including premature infants, polyarthritis, pleural effusion, septic shock, cholestasis, and cholestatic jaundice, that warrant further investigation. These findings support deeper analysis of the relationship between methimazole and adverse events and may help improve patient safety and clinical outcomes.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.003
metaresearch head score (Gemma)0.005
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.006
Threshold uncertainty score0.014

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0030.005
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0020.002
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.001
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.010
GPT teacher head0.257
Teacher spread0.247 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueFrontiers in EndocrinologySame topicThyroid Disorders and TreatmentsFrench-language works237,207